Strategic partnership with In-Q-Tel plays key role in introducing cutting-edge optical mapping technologies to the intelligence community
Madison, WI - October 29, 2007 - OpGen, Inc. the leader in microbial genome analysis today announced a strategic investment and development agreement with In-Q-Tel, the independent strategic investment firm that identifies innovative technology solutions to support the mission of the broader U.S. Intelligence Community. This agreement allows for development and enhancement of new optical mapping systems.
“OpGen’s microbial genome analysis technology has been used by commercial, academic, and governmental organizations worldwide, on a service basis, since the company’s inception,” said Colin Dykes, OpGen’s Chief Scientific Officer. “This strategic agreement with In-Q-Tel provides further validation of our technology and dovetails perfectly with OpGen’s move towards delivering stand-alone instruments and disposables for microbial analysis.”
"OpGen is an important addition to our strategic investment portfolio," said Troy M. Pearsall, Executive Vice President of Technology Transfer at In-Q-Tel. "As part of our charter, In-Q-Tel evaluates innovative technology advances with specific applicability to the challenges facing the U.S. Intelligence Community. OpGen’s technology will significantly improve the user’s ability to analyze organisms. In-Q-Tel is pleased to be partnering with OpGen, and we are impressed with their significant developments in microbial genome analysis."
OpGen delivers breakthrough capabilities to identify microorganisms using a unique method to analyze DNA extracted directly from the microbial cells. The system has been used by a wide range of organizations to study bacteria, fungi and other organisms important to human health.
The In-Q-Tel investment is linked to OpGen’s recent funding round led by CHL Medical Partners, Highland Capital Partners and Versant Ventures, with previous investor Mason Wells also participating.
OpGen is commercializing a novel single molecule DNA analysis technology, "Optical Mapping", for rapid identification and analysis of microorganisms. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning, or probes. Applications of the new commercial systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products. For more information, please visit www.opgen.com or call 608-441-8100.
In-Q-Tel is a strategic, not-for-profit investment firm that works to identify, adapt, and deliver innovative technology solutions to support the mission of the U.S. Intelligence Community. Launched by the CIA in 1999 as a private, independent organization, In-Q-Tel’s mission is to identify and partner with companies developing cutting-edge technologies that serve the national security interests of the United States. Working from an evolving strategic blueprint defining the Intelligence Community’s critical technology needs, In-Q-Tel engages with entrepreneurs, growth companies, researchers, and investors to deliver technologies that provide superior capabilities for the CIA and the larger Intelligence Community. In-Q-Tel concentrates on several broad commercial technology areas, including application software and analytics; communications and infrastructure; embedded systems and power; and bio, chemical, and nanotechnology. To date, In-Q-Tel has engaged with more than 100 companies and delivered more than 140 technology solutions to the Intelligence Community. To learn more about In-Q-Tel, visit www.iqt.org.